Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036

Akebia Therapeutics, Inc. (AKBA) Strengthens Vafseo Patent Protection Through 2036 Laiba Immad Tue, June 30, 2026 at 8:10 PM GMT+7 2 min read AKBA We recently compiled a list of the 12 Best Low-Priced Pharma Stocks to Buy Right Now. Akebia Therapeutics, Inc. (NASDAQ:AKBA) is one of the best low-priced pharma stocks on this list.

The Fly reported on June 10 that AKBA strengthened the intellectual property protection for its flagship therapy, Vafseo (vadadustat), after receiving a new patent listing in the FDA's Orange Book and notification of eligibility for a five-year extension of a composition of matter patent. The additions enhance the company's existing patent portfolio, which now includes 14 Orange Book-listed patents covering Vafseo with protection extending through 2036. These developments further support the company's efforts to protect the long-term value and commercial potential of the therapy.

Earlier on May 7, Akebia Therapeutics, Inc. (NASDAQ:AKBA) reported its first-quarter 2026 financial results, highlighting continued progress for Vafseo and its kidney disease pipeline. Vafseo net product revenue reached $15.8 million during the quarter, while the number of patients using the therapy increased approximately 60% compared with the end of the prior quarter. The company also reported around 1,025 prescribers, representing a 28% increase from Q4 2025. Total first-quarter revenue was $53.5 million, compared with $57.3 million in the same period last year. AKBA continued advancing clinical programs, including praliciguat in FSGS and AKB-097 in rare kidney diseases, while maintaining cash resources of approximately $162.6 million as of March 31, 2026.